Table 2.
Patient information of training set and validation set.
| Train Set | Validation Set | |||
|---|---|---|---|---|
|
non-cancer, N = 581 |
lung cancer, N = 1261 |
non-cancer, N = 241 |
lung cancer, N = 531 |
|
| Gender | ||||
| Female | 17/58 (29%) | 64/126 (51%) | 12/24 (50%) | 32/53 (60%) |
| Male | 41/58 (71%) | 62/126 (49%) | 12/24 (50%) | 21/53 (40%) |
| Age (years) | 39.19 (8.64) | 57.12 (11.95) | 39.83 (9.66) | 56.45 (11.96) |
| cfDNA concentration (ng/mL) | 11.72 (6.51) | 22.87 (46.16) | 9.18 (3.52) | 22.69 (30.94) |
| Stage | ||||
| Tis | 6/124 (4.8%) | 1/52 (1.9%) | ||
| I | 103/124 (83%) | 42/52 (81%) | ||
| II | 11/124 (8.9%) | 6/52 (12%) | ||
| III | 1/124 (0.8%) | 2/52 (3.8%) | ||
| IV | 3/124 (2.4%) | 1/52 (1.9%) | ||
| (Missing) | 58 | 2 | 24 | 1 |
| Subtype | ||||
| LUAD | 101/109 (93%) | 44/50 (88%) | ||
| LUSC | 8/109 (7.3%) | 6/50 (12%) | ||
| (Missing) | 58 | 17 | 24 | 3 |
1n/N (%); Mean (SD).